



## Corrigendum

## Corrigendum to “Indirect effects of paediatric conjugate vaccines on invasive pneumococcal disease in older adults” [Int J Infect Dis 86 (2019) 122–130]



Pilar Ciruela<sup>a,b,\*</sup>, Sonia Broner<sup>a</sup>, Conchita Izquierdo<sup>a</sup>, Roman Pallarés<sup>c,d</sup>,  
Carmen Muñoz-Almagro<sup>b,e,f</sup>, Sergi Hernández<sup>a</sup>, Imma Grau<sup>c,d</sup>, Angela Domínguez<sup>b,g</sup>,  
Mireia Jané<sup>a</sup>, The Catalan Working Group on Invasive Pneumococcal Disease<sup>1</sup>

<sup>a</sup> Agència de Salut Pública de Catalunya, Generalitat de Catalunya, C/Roc Boronat, 81–95, 08005 Barcelona, Spain

<sup>b</sup> CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, C/Monforte de Lemos, 3–5, 28029 Madrid, Spain

<sup>c</sup> Hospital Universitari Bellvitge, Universitat de Barcelona, C/Feixa Llarga s/n 08907, L'Hospitalet, Barcelona, Spain

<sup>d</sup> CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, C/Monforte de Lemos, 3–5, 28029 Madrid, Spain

<sup>e</sup> Hospital Universitari Sant Joan de Déu, Pg. Sant Joan de Déu 2, 08950 Esplugues, Barcelona, Spain

<sup>f</sup> Department of Medicine, Universitat Internacional de Catalunya, C/Josep Trueta, s/n 08195 Sant Cugat del Vallès, Barcelona, Spain

<sup>g</sup> Departament de Medicina, Universitat de Barcelona, C/Casanova, 143, 08036 Barcelona, Spain

The authors regret that the article was published with errors in Table 3.

The Comorbidities >1 at-risk condition and >1 high-risk condition rows should be replaced with  $\geq 1$  at-risk condition and  $\geq 1$  high-risk condition, respectively.

For the Serotype categories PCV13 row, the percentages, which read “54.5 and 245.5” should be replaced with “20.1 and 79.9”, respectively.

For the Penicillin Susceptible row, the total number which read “284” and the percentages which read “21.5 and 78.5” should be replaced with “778” and “15.4 and 84.6”, respectively.

For the Penicillin Non-susceptible row the total number which read “778” and the percentages which read “15.4 and 84.6” should be replaced with “284” and “21.5 and 78.5”, respectively.

For the Cefotaxime Susceptible row, the total number which read “127” and the percentages which read “23.6 and 76.4” should be replaced with “935” and “16.1 and 83.9”, respectively.

For the Cefotaxime Non-susceptible row, the total number which read “935” and the percentages which read “16.1 and 83.9” should be replaced with “127” and “23.6 and 76.4”, respectively.

This article was corrected online.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <http://dx.doi.org/10.1016/j.ijid.2019.06.030>

\* Corresponding author at: Agència de Salut Pública de Catalunya, Generalitat de Catalunya, C/Roc Boronat, 81–95, 08005 Barcelona, Spain.

E-mail address: [pilar.ciruela@gencat.cat](mailto:pilar.ciruela@gencat.cat) (P. Ciruela).

<sup>1</sup> See list of collaborators in the original article.

<http://dx.doi.org/10.1016/j.ijid.2019.12.027>

1201-9712/© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. All rights reserved.